| HOME >> BIOLOGY >> TECHNOLOGY |
Table 3.108: Variation of CF Detection Rates by Ethnic Background 160
Table 3.109: Global Market for CF Diagnostic Testing, 2000-2008 161
Table 3.110: U.S. Market for CF Diagnostic Testing, 2000-2008 161
Table 3.111: Projected Global Market for CF Diagnostic Testing, 2009-2013 161
Table 3.112: Projected U.S. Market for CF Diagnostic Testing, 2009-2013 161
Table 3.113: Commercial CF-Screening Products 162
Table 3.114: CF Screening Technology Summary 162
Table 3.115: U.S. Market for HLA Type Testing, 2000-2009 165
Table 3.116: Competitors in HLA Testing 165
Table 3.117: Carrier Rates of Common HFE Mutations in Caucasians 167
Table 3.118: Results and Diagnosis for Fragile X Syndrome 169
Table 3.119: Other Genetic Testing Procedures by Molecular Diagnostics 170
Table 3.120: DNA Chip Market Drivers and Restraints 171
Table 3.121: DNA Chip Major Players 172
Table 3.122: Applications of DNA Biochips 172
Table 3.123: Technology Trends in the DNA Microarray Market 174
Table 3.124: Molecular Diagnostic Personalized Medicine Tests 177
Table 3.125: Global Revenue Forecasts for Prenatal and Newborn Testing Segment,
2007-2015 181
Table 3.126: Various Molecular Diagnostics Technologies: Timeline for Impact 182
Table 3.127: Various Molecular Diagnostics Technologies: Impact on Different
Therapeutic Areas in Personalized Medicine 183
Table 3.128: Various Molecular Diagnostics Technologies: Technical Challenges in
the Deployment for Personalized Medicine 183
Table 4.1: DNA-Sequencing Molecular Diagnostics Market Players 188
Table 4.2: U.S. Market for DNA Chips, 2000-2015 189
Table 4.3: Affymetrix DNA Analysis Products 190
Table 4.4: PCR Segmentation by Sector 198
Table 4.5: Impediments to Incorporating Promising Molecular Tests into Clinical
Prac
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |